archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • CSL Half Year Report 2012-13
    News Alert Search News by Date Contact CSL Home Newsroom CSL Half Year Report 2012 13 CSL Half Year Report 2012 13 Melbourne Australia 05 04 2013 Insert Copy Download this release CSL Half Year Results Announcement for 2012 13 0 30Mb Additional resources The Webcast Analyst presentation and Half Year information is also available More For further information please contact Media Sharon McHale Senior Director Public Affairs CSL Limited

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1255931130326/prdetail.htm (2014-01-05)
    Open archived version from archive


  • New US$500 million Private Placement
    Private Placement Melbourne Australia 28 03 2013 CSL Limited ASX CSL is pleased to announce that on 27 March 2013 it closed a new US 500m Private Placement in the US The Private Placement was foreshadowed in CSL s half year announcement in February 2013 The Private Placement consists of four maturities as follows 5 yr Bullet 7 yr Bullet 10 yr Bullet 12 yr Bullet Amount US 100m US 150m US 150m US 100m Coupon 2 07 2 57 3 20 3 32 The Private Placement has a weighted average interest rate of 2 81 and average life of 8 5 years The maturities achieved will fill gaps in the Group s current debt maturity profile as shown below The Private Placement was well received by investors with a significant level of oversubscription CSL s Chief Financial Officer Gordon Naylor said We were very pleased to achieve a good outcome for the Company which has enabled us to significantly strengthen our debt maturity profile at very attractive long term interest rates We are grateful for the support of this important debt market which has recognised the sustainability of our business model The proceeds from the Private Placement will be

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1255931072367/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Terms of Appointment of Managing Director and CEO
    Managing Director and CEO Melbourne Australia 08 03 2013 CSL Limited ASX CSL has previously announced that Mr Paul Perreault will succeed Dr Brian McNamee as Managing Director and Chief Executive Officer of CSL from 1 July 2013 Mr Perreault s main terms and conditions on commencement in his new role of Managing Director and Chief Executive Officer are summarised in the PDF below Mr Perreault s remuneration will continue

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1255930934343/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Half-Year results Announcements 2012/13
    02 2013 CSL Limited ASX CSL today announced a net profit after tax of US 627 million for the six months ended 31 December 2012 up US 123 million or 24 on a reported basis when compared to the prior comparable period PCP Earnings per share grew 30 benefiting from current and past capital management initiatives Download this release CSL Half Year Results Announcement for 2012 13 0 30Mb Additional

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1255930783246/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Half-Year results Announcements 2012/13
    Director effective 13 February 2013 Mr Perreault currently holds the position of President CSL Behring and as announced on 3 August 2012 he will succeed Dr Brian McNamee as Managing Director and Chief Executive Officer of CSL on 1 July 2013 Professor John Shine AO Chairman of CSL said today As President of CSL Behring Paul has consistently delivered results and has driven exceptional growth He is recognised as an

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1255930793652/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Change to 2013 Dividend Payment Dates
    of its Half Year and Full Year Results Announcements by one week it will also bring forward the payment date of its interim and full year dividends by one week CSL s revised Financial Calendar is set out below 13 February 2013 Half year profit and interim dividend announcement 05 March 2013 Shares traded ex dividend 12 March 2013 Record date for interim dividend 05 April 2013 Interim dividend paid

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1255930792511/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL Biotherapies provides update on Fluvax® investigation
    to be associated with a higher rate of fever in children compared to at least one other licensed influenza vaccine but that Fluvax had not been previously linked to a significant risk of febrile convulsion 2 3 CSL s extensive manufacturing investigations which reviewed all aspects of the manufacturing process from starting materials through to finished product did not identify any raw material issues process changes or deviations from the CSL standard method of manufacture that explained the increased adverse reactions in children in 2010 CSL s preliminary conclusion is that its standard method of manufacture retains more virus components than that of other manufacturers and that the particular characteristics of the 2010 virus components elicited an excessive immune response in some young children triggering increased fever and fever related convulsions Dr Darryl Maher Vice President of Medical and Research at CSL Biotherapies says While influenza vaccines must contain virus components to stimulate sufficient protection against influenza it appears that components of the inactivated virus retained in Fluvax in 2010 overstimulated the developing immune systems of some young children compared to previous seasons The preliminary conclusion is underpinned by comprehensive scientific studies into the virus disruption splitting process of CSL s method of manufacture CSL has found in laboratory experiments that increasing the amount of splitting agent used can reduce the amount of reactive virus components in Fluvax CSL is undertaking ongoing studies to understand how the characteristics of the reactive virus components in Fluvax contributed to the adverse events in children in 2010 and to further investigate process changes that will adequately reduce them It will take some time to complete this work and to fully evaluate the impact and acceptability of any process modifications made It is important that such changes not only make Fluvax safe and effective for children but that they also retain the current protective benefits of Fluvax for adults and the elderly The investigations have been complex because of the multiple biological factors involved There is more work to do but we have made substantial progress in both isolating the cause of the adverse events and identifying potential process changes that will prevent them from happening again says Dr Maher Until these further studies are completed and both CSL and the regulators are fully confident that our manufacturing process can consistently produce a safe and effective influenza vaccine for children we will continue to fully support the age restrictions currently in place for children in all markets says Dr Maher Fluvax is not licensed for use in children aged under 5 years and is only recommended for at risk children aged between 5 and 9 years if no other licensed influenza vaccine is available A recent review conducted by the Australian Technical Advisory Group on Immunisation ATAGI found that Fluvax continues to have an acceptable safety profile in people aged 10 years and over This is consistent with previous published clinical studies and CSL s ongoing global safety monitoring 4 5 6 Influenza is

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1255929042869/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL Limited's Global Leadership Group
    the US and responsible for CSL Behring s global supply chain the supply of plasma for CSL Behring and CSL s global information systems Andrew Cuthbertson BMedSci MBBS PhD Age 57 Chief Scientific Officer and R D Director Andrew was appointed as Chief Scientific Officer and R D Director in 2000 He is responsible for CSL s global Research and Development operations Andrew joined CSL in 1997 as Director of Research He trained in medicine and science at the University of Melbourne the Walter and Eliza Hall Institute the Howard Florey Institute and the National Institutes of Health in the US Andrew was then a Senior Scientist at Genentech Inc in San Francisco Mary Sontrop BAppSc Grad Dip Health Admin Grad Dip Quality Mgt MBA Age 56 Executive Vice President Manufacturing and Planning Mary was appointed as Executive Vice President Manufacturing and Planning in 2010 She joined CSL as a Production Manager in 1988 and has held a broad range of positions in manufacturing quality management and general management located in Australia Switzerland and Germany Prior to her current position Mary was General Manager of CSL Biotherapies for Australia and New Zealand Ingolf Sieper MD BA Age 58 Executive Vice President Commercial Operations Ingolf was appointed Executive Vice President Commercial Operations in 2011 He is responsible for all sales and marketing activities globally for CSL Behring Ingolf joined a CSL predecessor company in 1986 and has a strong background in marketing and management in the coagulation diagnostic and plasma protein divisions Among the roles in which he has served Ingolf was Vice President and General Manager Commercial Operations Central Europe with responsibility for CSL Behring s commercial activities in Germany Switzerland Austria and Slovenia Karen Etchberger PhD Age 55 Executive Vice President Quality and Business Services Karen was appointed as

    Original URL path: http://www.csl.com.au/about/board-management/global-leadership-group.htm (2014-01-05)
    Open archived version from archive